BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 30851065)

  • 1. Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system.
    Delimitsou A; Fostira F; Kalfakakou D; Apostolou P; Konstantopoulou I; Kroupis C; Papavassiliou AG; Kleibl Z; Stratikos E; Voutsinas GE; Yannoukakos D
    Hum Mutat; 2019 May; 40(5):631-648. PubMed ID: 30851065
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Functional Analysis Identifies Damaging CHEK2 Missense Variants Associated with Increased Cancer Risk.
    Boonen RACM; Wiegant WW; Celosse N; Vroling B; Heijl S; Kote-Jarai Z; Mijuskovic M; Cristea S; Solleveld-Westerink N; van Wezel T; Beerenwinkel N; Eeles R; Devilee P; Vreeswijk MPG; Marra G; van Attikum H
    Cancer Res; 2022 Feb; 82(4):615-631. PubMed ID: 34903604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline CHEK2 Gene Mutations in Hereditary Breast Cancer Predisposition - Mutation Types and their Biological and Clinical Relevance.
    Kleiblová P; Stolařová L; Křížová K; Lhota F; Hojný J; Zemánková P; Havránek O; Vočka M; Černá M; Lhotová K; Borecká M; Janatová M; Soukupová J; Ševčík J; Zimovjanová M; Kotlas J; Panczak A; Veselá K; Červenková J; Schneiderová M; Burócziová M; Burdová K; Stránecký V; Foretová L; Macháčková E; Tavandzis S; Kmoch S; Macůrek L; Kleibl Z
    Klin Onkol; 2019; 32(Supplementum2):36-50. PubMed ID: 31409080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to DNA damage of CHEK2 missense mutations in familial breast cancer.
    Roeb W; Higgins J; King MC
    Hum Mol Genet; 2012 Jun; 21(12):2738-44. PubMed ID: 22419737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rare, evolutionarily unlikely missense substitutions in CHEK2 contribute to breast cancer susceptibility: results from a breast cancer family registry case-control mutation-screening study.
    Le Calvez-Kelm F; Lesueur F; Damiola F; Vallée M; Voegele C; Babikyan D; Durand G; Forey N; McKay-Chopin S; Robinot N; Nguyen-Dumont T; Thomas A; Byrnes GB; ; Hopper JL; Southey MC; Andrulis IL; John EM; Tavtigian SV
    Breast Cancer Res; 2011 Jan; 13(1):R6. PubMed ID: 21244692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional and genomic approaches reveal an ancient CHEK2 allele associated with breast cancer in the Ashkenazi Jewish population.
    Shaag A; Walsh T; Renbaum P; Kirchhoff T; Nafa K; Shiovitz S; Mandell JB; Welcsh P; Lee MK; Ellis N; Offit K; Levy-Lahad E; King MC
    Hum Mol Genet; 2005 Feb; 14(4):555-63. PubMed ID: 15649950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHEK2 variants: linking functional impact to cancer risk.
    Boonen RACM; Vreeswijk MPG; van Attikum H
    Trends Cancer; 2022 Sep; 8(9):759-770. PubMed ID: 35643632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of deleterious germline CHEK2 mutations and their association with breast and ovarian cancer.
    Kleiblova P; Stolarova L; Krizova K; Lhota F; Hojny J; Zemankova P; Havranek O; Vocka M; Cerna M; Lhotova K; Borecka M; Janatova M; Soukupova J; Sevcik J; Zimovjanova M; Kotlas J; Panczak A; Vesela K; Cervenkova J; Schneiderova M; Burocziova M; Burdova K; Stranecky V; Foretova L; Machackova E; Tavandzis S; Kmoch S; Macurek L; Kleibl Z
    Int J Cancer; 2019 Oct; 145(7):1782-1797. PubMed ID: 31050813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk.
    Stolarova L; Kleiblova P; Zemankova P; Stastna B; Janatova M; Soukupova J; Achatz MI; Ambrosone C; Apostolou P; Arun BK; Auer P; Barnard M; Bertelsen B; ; Blok MJ; Boddicker N; Brunet J; Burnside ES; Calvello M; Campbell I; Chan SH; Chen F; Chiang JB; Coppa A; Cortesi L; Crujeiras-González A; ; De Leeneer K; De Putter R; DePersia A; Devereux L; Domchek S; Efremidis A; Engel C; Ernst C; Evans DGR; Feliubadaló L; Fostira F; Fuentes-Ríos O; Gómez-García EB; González S; Haiman C; Hansen TVO; Hauke J; Hodge J; Hu C; Huang H; Ishak NDB; Iwasaki Y; Konstantopoulou I; Kraft P; Lacey J; Lázaro C; Li N; Lim WK; Lindstrom S; Lori A; Martinez E; Martins A; Matsuda K; Matullo G; McInerny S; Michailidou K; Montagna M; Monteiro ANA; Mori L; Nathanson K; Neuhausen SL; Nevanlinna H; Olson JE; Palmer J; Pasini B; Patel A; Piane M; Poppe B; Radice P; Renieri A; Resta N; Richardson ME; Rosseel T; Ruddy KJ; Santamariña M; Dos Santos ES; Teras L; Toland AE; Trentham-Dietz A; Vachon CM; Volk AE; Weber-Lassalle N; Weitzel JN; Wiesmuller L; Winham S; Yadav S; Yannoukakos D; Yao S; Zampiga V; Zethoven M; Zhang ZW; Zima T; Spurdle AB; Vega A; Rossing M; Del Valle J; De Nicolo A; Hahnen E; Claes KBM; Ngeow J; Momozawa Y; James PA; Couch FJ; Macurek L; Kleibl Z
    Clin Cancer Res; 2023 Aug; 29(16):3037-3050. PubMed ID: 37449874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis and ACMG-based classification of CHEK2 variants in hereditary cancer patients.
    Vargas-Parra G; Del Valle J; Rofes P; Gausachs M; Stradella A; Moreno-Cabrera JM; Velasco A; Tornero E; Menéndez M; Muñoz X; Iglesias S; López-Doriga A; Azuara D; Campos O; Cuesta R; Darder E; de Cid R; González S; Teulé A; Navarro M; Brunet J; Capellá G; Pineda M; Feliubadaló L; Lázaro C
    Hum Mutat; 2020 Dec; 41(12):2128-2142. PubMed ID: 32906215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole Genome Sequencing Prioritizes
    Srivastava A; Giangiobbe S; Skopelitou D; Miao B; Paramasivam N; Diquigiovanni C; Bonora E; Hemminki K; Försti A; Bandapalli OR
    Front Endocrinol (Lausanne); 2021; 12():600682. PubMed ID: 33692755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHEK2 contribution to hereditary breast cancer in non-BRCA families.
    Desrichard A; Bidet Y; Uhrhammer N; Bignon YJ
    Breast Cancer Res; 2011; 13(6):R119. PubMed ID: 22114986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Germline CHEK2 Gene Variants with Risk and Prognosis of Non-Hodgkin Lymphoma.
    Havranek O; Kleiblova P; Hojny J; Lhota F; Soucek P; Trneny M; Kleibl Z
    PLoS One; 2015; 10(10):e0140819. PubMed ID: 26506619
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Stolarova L; Kleiblova P; Janatova M; Soukupova J; Zemankova P; Macurek L; Kleibl Z
    Cells; 2020 Dec; 9(12):. PubMed ID: 33322746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients.
    Apostolou P; Fostira F; Mollaki V; Delimitsou A; Vlassi M; Pentheroudakis G; Faliakou E; Kollia P; Fountzilas G; Yannoukakos D; Konstantopoulou I
    J Hum Genet; 2018 Jul; 63(8):877-886. PubMed ID: 29785007
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and characterization of novel SNPs in CHEK2 in Ashkenazi Jewish men with prostate cancer.
    Tischkowitz MD; Yilmaz A; Chen LQ; Karyadi DM; Novak D; Kirchhoff T; Hamel N; Tavtigian SV; Kolb S; Bismar TA; Aloyz R; Nelson PS; Hood L; Narod SA; White KA; Ostrander EA; Isaacs WB; Offit K; Cooney KA; Stanford JL; Foulkes WD
    Cancer Lett; 2008 Oct; 270(1):173-80. PubMed ID: 18571837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First evidence of a large CHEK2 duplication involved in cancer predisposition in an Italian family with hereditary breast cancer.
    Tedaldi G; Danesi R; Zampiga V; Tebaldi M; Bedei L; Zoli W; Amadori D; Falcini F; Calistri D
    BMC Cancer; 2014 Jul; 14():478. PubMed ID: 24986639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
    Wagener R; Walter C; Auer F; Alzoubi D; Hauer J; Fischer U; Varghese J; Dugas M; Borkhardt A; Brozou T
    Int J Cancer; 2023 Apr; 152(7):1388-1398. PubMed ID: 36468172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of the c.793-1G > A splicing variant in CHEK2 gene as pathogenic: a case report.
    Agiannitopoulos K; Papadopoulou E; Tsaousis GN; Pepe G; Kampouri S; Kocdor MA; Nasioulas G
    BMC Med Genet; 2019 Jul; 20(1):131. PubMed ID: 31349801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.